Tenaya Therapeutics is trading at $0.65, up 9.59%, in pre-market on September 30, 2026; the catalyst remains unclear. - No company-specific announcement dated September 30, 2026, was found in the available search results. - The latest identified major company news was the FDA’s September 14 RMAT designation for TN-401, which predates this move. - Supplied broad-market indicators are modestly positive but do not establish a clear cause for the stock’s gain.